Project Grant R01HL179324
Award Date 7/21/25
Completion Date 6/30/30
Dollars Obligated $762K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This $247,500 project grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to develop a non-invasive model for early detection of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). The research aims to leverage proteomic analysis of plasma samples from ARDS patient cohorts to derive and validate a classifier that can accurately identify PVD, a high-risk ARDS subgroup with...
- This federal Project Grant award, titled "RESILIENCE ENDOTYPE-DERIVATION THROUGH PARSIMONIOUS ANALYSIS AND CAUSAL INFERENCE OF RECOVERY FROM ACUTE RESPIRATORY DISTRESS SYNDROME (REPAIR-ARDS)", is funded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) in the amount of $674,351. The project aims to develop predictive models for early diagnosis of Acute Respiratory Distress Syndrome (ARDS) using protein biomarkers and clinical data, as...
- This federal Project Grant award of $1,479,335.00 from the National Heart Lung and Blood Institute under CFDA 93.837 Cardiovascular Diseases Research aims to leverage observational data and advanced machine learning methods to address gaps in understanding and personalizing treatment for Acute Respiratory Distress Syndrome (ARDS). The key products and services to be delivered include: Developing improved methods for ARDS phenotyping using dynamic clinical data to better understand prognosis...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $791,503 to Weill Medical College of Cornell University to conduct research on the role of the thrombin receptor protease activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS). The 4-year award, effective September 15, 2025, aims to investigate a previously unappreciated function of PAR1 in the lung lymphatic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
- This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...
- This $775,992 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells and glucocorticoids in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through regulatory T cells impacts the recovery of lung structure and function following...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to investigate the impact of glycocalyx degradation on the pathogenesis and outcomes of Acute Respiratory Distress Syndrome (ARDS). The award of $188,740 to the University of Pittsburgh aims to establish a framework for translating discoveries about the role of the pulmonary endothelial and epithelial glycocalyces in ARDS into...
- This Project Grant award of $153,099.00 from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) is funding research to use target trial emulation and g-methods for causal inference from observational data to address gaps in knowledge about the care of patients with acute respiratory distress syndrome (ARDS), with a focus on evaluating dynamic treatment regimes for steroid initiation, duration, and dosing. The research will utilize data...